Proteomics

Dataset Information

0

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

ABSTRACT: Human breast cancer cell lines were cultured in phenol red-free RPMI1640 medium supplemented with 10% fetal bovine serum and 1nM E2. All cell lines were banked in multiple aliquots to reduce the risk of phenotypic drift and identity confirmed using STR. Cells were routinely screened for mycoplasma contamination. Long-term E deprived (LTED) cells modelling resistance to an AI were derived from all parental cell lines as previously described. Two models of MCF7-LTED cells were available: one harbouring a Y537C mutation in ESR1 and the other with wt-ESR1. SUM44-LTED was shown to harbour a natural heterozygous ESR1Y537S mutation. Elacestrant resistant cell lines were generated by growing parental cells (MCF7-LTEDY537C) long-term in the presence of RPMI1640 containing 10% DCC + 0.1nM E2 + 1μM elacestrant. All cell lines were stripped of steroids for 48-72 hours prior to the start of experiments.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Nikiana Simigdala  

LAB HEAD: Lesley-Ann Martin

PROVIDER: PXD031377 | Pride | 2023-03-10

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

Pancholi Sunil S   Simigdala Nikiana N   Ribas Ricardo R   Schuster Eugene E   Leal Mariana Ferreira MF   Nikitorowicz-Buniak Joanna J   Rega Camilla C   Bihani Teeru T   Patel Hitisha H   Johnston Stephen R SR   Dowsett Mitch M   Martin Lesley-Ann LA  

NPJ breast cancer 20221129 1

The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD elacestrant, versus fulvestrant, demonstrates both drugs impact tumour growth of ER+ patient-derived xenograft models harbouring several ESR1 mutations but that elacestrant is active after acquired resistance to fulvestrant. In cell line models of endocrine sensitive and resis  ...[more]

Similar Datasets

Proteomics Quantitative proteomics on wt-MCF7 versus their LTED derivatives using dimethyl labelling
2016-06-01 | PXD004085 | Pride
Proteomics ER-RIME in wt-MCF7 and MCF7-LTED
2020-07-13 | PXD004648 | Pride
Unknown Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines [ChIP-Seq]
2018-01-12 | GSE100074 | GEO
Unknown Discovery of naturally occurring ESR1 mutations during acquisition of resistance to endocrine therapy in widely used estrogen receptor positive breast cancer cell lines [RNA-Seq]
2018-01-12 | GSE100075 | GEO
Proteomics,Multiomics Comparative shotgun proteomics in wt-SUM44 and SUM44-LTED, using RIME and dimethyl-labelling
2017-12-11 | PXD004807 | Pride
Proteomics,Multiomics Resistance to Palbociclib requires multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome
2020-03-25 | PXD005611 | Pride
Genomics
| PRJNA543962 | ENA
Unknown Transcriptomic profiles of MCF7-derived tamoxifen resistant cell lines
2023-10-25 | GSE241654 | GEO
Unknown Heat Shock Factor 1 (HSF1) supports the ESR1 action in breast cancer (ChIP-seq)
2021-10-21 | GSE159724 | GEO
Unknown Heat Shock Factor 1 (HSF1) regulates ESR1 action in breast cancer
2021-12-18 | GSE186004 | GEO